Literature DB >> 23281295

Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study.

Bharath Manu Akkara Veetil1, Elena Myasoedova, Eric L Matteson, Sherine E Gabriel, Abigail B Green, Cynthia S Crowson.   

Abstract

OBJECTIVE: To determine the incidence, time trends, risk factors, and severity of herpes zoster in a population-based cohort of patients with newly diagnosed rheumatoid arthritis (RA) compared to a group of individuals without RA from the same population.
METHODS: All residents of Olmsted County, Minnesota fulfilling for the first time the 1987 American College of Rheumatology criteria for RA between January 1, 1980 and December 31, 2007 and a cohort of similar residents without RA were assembled and followed by retrospective chart review until death, migration, or December 31, 2008.
RESULTS: There was no difference in the presence of herpes zoster prior to the RA incidence/index date between the cohorts (P = 0.85). During followup, 84 patients with RA (rate 12.1 cases per 1,000 person-years) and 44 subjects without RA (rate 5.4 cases per 1,000 person-years) developed herpes zoster. Patients with RA were more likely to develop herpes zoster than those without RA (hazard ratio [HR] 2.4 [95% confidence interval (95% CI) 1.7-3.5]). Herpes zoster occurred more frequently in patients diagnosed with RA more recently (HR 1.06 per year [95% CI 1.02-1.10]). Erosive disease, previous joint surgery, and use of hydroxychloroquine and corticosteroids were significantly associated with the development of herpes zoster in RA. There was no apparent association of herpes zoster with the use of methotrexate or biologic agents. Complications of herpes zoster occurred at a similar rate in both cohorts.
CONCLUSION: The incidence of herpes zoster is increased in RA and has risen in recent years. There also has been an increasing incidence of herpes zoster in more recent years in the general population. RA disease severity is associated with the development of herpes zoster.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23281295      PMCID: PMC3674119          DOI: 10.1002/acr.21928

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  26 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  History of the Rochester Epidemiology Project.

Authors:  L J Melton
Journal:  Mayo Clin Proc       Date:  1996-03       Impact factor: 7.616

3.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

4.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

5.  Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate.

Authors:  M A Antonelli; L W Moreland; J E Brick
Journal:  Am J Med       Date:  1991-03       Impact factor: 4.965

6.  Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.

Authors:  F Wolfe; K Michaud; E F Chakravarty
Journal:  Rheumatology (Oxford)       Date:  2006-09-26       Impact factor: 7.580

7.  Extra-articular rheumatoid arthritis: prevalence and mortality.

Authors:  C Turesson; L Jacobsson; U Bergström
Journal:  Rheumatology (Oxford)       Date:  1999-07       Impact factor: 7.580

8.  Racial and psychosocial risk factors for herpes zoster in the elderly.

Authors:  K Schmader; L K George; B M Burchett; C F Pieper
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

9.  Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis.

Authors:  J H Dobloug; O Førre; T K Kvien; T Egeland; M Degré
Journal:  Ann Rheum Dis       Date:  1982-10       Impact factor: 19.103

10.  Varicella and herpes zoster in Madrid, based on the Sentinel General Practitioner Network: 1997-2004.

Authors:  Napoleón Pérez-Farinós; María Ordobás; Cristina García-Fernández; Luis García-Comas; Soledad Cañellas; Inmaculada Rodero; Angeles Gutiérrez-Rodríguez; Juan García-Gutiérrez; Rosa Ramírez
Journal:  BMC Infect Dis       Date:  2007-06-15       Impact factor: 3.090

View more
  20 in total

1.  Association of Asthma with Rheumatoid Arthritis: A Population-Based Case-Control Study.

Authors:  Youn Ho Sheen; Mary C Rolfes; Chung-Il Wi; Cindy S Crowson; Richard S Pendegraft; Katherine S King; Euijung Ryu; Young J Juhn
Journal:  J Allergy Clin Immunol Pract       Date:  2017-08-09

Review 2.  Infection Risk and Safety of Corticosteroid Use.

Authors:  Jameel Youssef; Shannon A Novosad; Kevin L Winthrop
Journal:  Rheum Dis Clin North Am       Date:  2015-10-24       Impact factor: 2.670

3.  Quantification of risk factors for herpes zoster: population based case-control study.

Authors:  Harriet J Forbes; Krishnan Bhaskaran; Sara L Thomas; Liam Smeeth; Tim Clayton; Sinéad M Langan
Journal:  BMJ       Date:  2014-05-13

4.  Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.

Authors:  Tsai-Ling Liao; Yi-Ming Chen; Hung-Jen Liu; Der-Yuan Chen
Journal:  BMJ Open       Date:  2017-01-05       Impact factor: 2.692

5.  Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.

Authors:  Kevin L Winthrop; Jeffrey R Curtis; Stephen Lindsey; Yoshiya Tanaka; Kunihiro Yamaoka; Hernan Valdez; Tomohiro Hirose; Chudy I Nduaka; Lisy Wang; Alan M Mendelsohn; Haiyun Fan; Connie Chen; Eustratios Bananis
Journal:  Arthritis Rheumatol       Date:  2017-09-06       Impact factor: 10.995

Review 6.  Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.

Authors:  Kunihiro Yamaoka
Journal:  Drug Saf       Date:  2016-09       Impact factor: 5.228

7.  Risk of Shingles in Adults with Primary Sjogren's Syndrome and Treatments: A Nationwide Population-Based Cohort Study.

Authors:  Jen-Yin Chen; Li-Kai Wang; Ping-Hsun Feng; Chin-Chen Chu; Tain-Junn Cheng; Shih-Feng Weng; Su-Zhen Wu; Tsung-Hsueh Lu; Chia-Yu Chang
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

Review 8.  Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review.

Authors:  Filippo Ansaldi; Cecilia Trucchi; Cristiano Alicino; Chiara Paganino; Andrea Orsi; Giancarlo Icardi
Journal:  Adv Ther       Date:  2016-06-04       Impact factor: 3.845

9.  Atypical Presentation of Disseminated Zoster in a Patient with Rheumatoid Arthritis.

Authors:  Nirav Patel; Davinder Singh; Krunal Patel; Shadab Ahmed; Prachi Anand
Journal:  Case Rep Med       Date:  2015-10-05

10.  Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.

Authors:  Fawziah Marra; Elaine Lo; Viktor Kalashnikov; Kathryn Richardson
Journal:  Open Forum Infect Dis       Date:  2016-09-28       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.